DALLAS and NEW YORK, Feb. 22, 2012 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. ACCP, a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that the Company will present at the Cowen and Company 32^nd Annual Health Care Conference, at The Boston Marriott Copley Place in Boston, MA, March 5-7, 2012.  The presentation is scheduled to take place on Wednesday, March 7th at 8:00am ET.

On Wednesday, Jeffrey Davis, Chief Executive Officer of Access Pharmaceuticals, will give a presentation updating investors on recent commercial advancements within its lead program for oral mucositis, MuGard, and highlights from its other product programs.  A live webcast of the audio presentation and company slide deck can be accessed via the following link during the presentation time: http://wsw.com/webcast/cowen6/accp/.

Management will be available to meet with investors or potential licensing partners March 5-7, 2012. To arrange a one-on-one meeting with Access management at the conference, please email Christine Berni, christine.berni@accesspharma.com.

About MuGard:

MuGard is a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments, characterized by inflammation and erythema or ulcerations throughout the oral mucosa.  For more information, please visit www.MuGard.com.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include MuGard™ (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac™, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine™, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.  

The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.  For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.

SOURCE Access Pharmaceuticals, Inc.